JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

Search

IQVIA Holdings Inc

Abrir

SetorSaúde

157.41 -0.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

156.24

Máximo

161.16

Indicadores-chave

By Trading Economics

Rendimento

182M

514M

Vendas

264M

4.4B

P/E

Médio do Setor

20.898

67.147

Margem de lucro

11.778

Funcionários

93,000

EBITDA

1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+43.33% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-12B

28B

Abertura anterior

157.64

Fecho anterior

157.41

Sentimento de Notícias

By Acuity

39%

61%

147 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 23:08 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 23:07 UTC

Ganhos

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:20 UTC

Ganhos

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 de abr. de 2026, 23:27 UTC

Conversa de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 de abr. de 2026, 23:22 UTC

Ganhos

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 de abr. de 2026, 22:52 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:33 UTC

Ganhos

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 de abr. de 2026, 22:05 UTC

Ganhos

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 21:57 UTC

Ganhos

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 de abr. de 2026, 21:55 UTC

Ganhos

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 de abr. de 2026, 21:53 UTC

Ganhos

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

43.33% parte superior

Previsão para 12 meses

Média 224.54 USD  43.33%

Máximo 255 USD

Mínimo 185 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

14

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

147 / 347 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat